Wilfried Mullens, Jeroen Dauw, Pieter Martens, Evelyne Meekers, Petra Nijst, Frederik H Verbrugge, Fabien Chenot, Samer Moubayed, Riet Dierckx, Philippe Blouard, David Derthoo, Walter Smolders, Bavo Ector, Michaël Hulselmans, Stijn Lochy, David Raes, Emeline Van Craenenbroeck, Hans Vandekerckhove, Pieter-Jan Hofkens, Kathleen Goossens, Anne-Catherine Pouleur, Michel De Ceuninck, Laurence Gabriel, Philippe Timmermans, Edgard A Prihadi, Frederik Van Durme, Michel Depauw, Delphine Vervloet, Els Viaene, Jean-Luc Vachiery, Katrien Tartaglia, Jozine M Ter Maaten, Liesbeth Bruckers, Walter Droogne, Pierre Troisfontaines, Kevin Damman, Johan Lassus, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, Matthias Dupont
AIMS: To describe the baseline characteristics of participants in the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial and compare these with other contemporary diuretic trials in acute heart failure (AHF). METHODS AND RESULTS: ADVOR recruited 519 patients with AHF, clinically evident volume overload, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) and maintenance loop diuretic therapy prior to admission. All participants received standardized loop diuretics and were randomized towards once daily intravenous acetazolamide (500 mg) versus placebo, stratified according to study centre and left ventricular ejection fraction (LVEF) (≤40% vs...
September 2022: European Journal of Heart Failure